TherapeuticsMD, Inc. (TXMD) Stock Price

TXMDStock

$1.90+81.82%52W

Market Cap$21.99M

P/E—

PEG Ratio—

Div yield—

Beta0.66

TXMD Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-19.86%

Price vs S&P 500 (4W)-8.20%

VGM Score54.46

P/CF (Annual)9.07x

Book Value / Share (Quarterly)$2.34

P/TBV (Annual)0.82x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-64.91%

Cash Flow / Share (Quarterly)$0.27

Price vs S&P 500 (YTD)4.64%

Gross Margin (TTM)100.00%

Net Profit Margin (TTM)-6.64%

EPS (TTM)$-0.02

10-Day Avg Trading Volume0.02M

EPS Excl Extra (TTM)$-0.02

Revenue Growth (5Y)-45.84%

EPS (Annual)$-0.05

ROI (Annual)-2.12%

Gross Margin (Annual)100.00%

Net Profit Margin (5Y Avg)-1496.19%

Cash / Share (Quarterly)$0.79

P/E Basic Excl Extra (TTM)135.01x

Revenue Growth QoQ (YoY)-8.72%

ROA (Last FY)-1.51%

Revenue Growth TTM (YoY)27.78%

EBITD / Share (TTM)$-0.31

ROE (5Y Avg)-328.15%

Operating Margin (TTM)-120.89%

Cash Flow / Share (Annual)$0.21

P/B Ratio0.81x

P/B Ratio (Quarterly)0.94x

Net Income / Employee (Annual)$-569,000

EV / Revenue (TTM)3.92x

Net Interest Coverage (TTM)-5.42x

ROA (TTM)-0.57%

EPS Growth QoQ (YoY)-72.06%

EV / EBITDA (TTM)0.21x

EPS Incl Extra (Annual)$-0.05

Current Ratio (Annual)3.02x

Quick Ratio (Quarterly)2.73x

3-Month Avg Trading Volume0.03M

52-Week Price Return81.82%

EV / Free Cash Flow (Annual)5.28x

P/E Incl Extra (TTM)135.01x

Revenue / Employee (TTM)$3,270,000

Tangible BV / Share (Quarterly)$2.04

P/S Ratio (Annual)7.28x

Asset Turnover (Annual)0.08x

52-Week High$2.95

Operating Margin (5Y Avg)-848.35%

EPS Excl Extra (Annual)$-0.05

Tangible BV CAGR (5Y)-28.85%

26-Week Price Return-9.95%

Quick Ratio (Annual)2.51x

13-Week Price Return-7.77%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)3.22x

Enterprise Value$12.80M

Revenue / Share Growth (5Y)-53.31%

Asset Turnover (TTM)0.09x

Book Value / Share Growth (5Y)-35.19%

Revenue / Employee (Annual)$3,022,000

Inventory Turnover (Annual)1.60x

Pretax Margin (Annual)-21.61%

Cash / Share (Annual)$0.65

3-Month Return Std Dev33.19%

Gross Margin (5Y Avg)81.23%

Net Income / Employee (TTM)$-217,000

ROE (Last FY)-2.12%

Net Interest Coverage (Annual)-9.43x

EPS Basic Excl Extra (Annual)$-0.05

P/FCF (TTM)7.05x

Receivables Turnover (TTM)-1.85x

EV / Free Cash Flow (TTM)4.10x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.02

Receivables Turnover (Annual)2.28x

ROI (TTM)-0.80%

P/S Ratio (TTM)6.73x

Pretax Margin (5Y Avg)-766.75%

Revenue / Share (Annual)$0.26

Tangible BV / Share (Annual)$2.00

Forward P/E11.18x

Price vs S&P 500 (52W)66.29%

P/E Ratio (TTM)135.01x

Year-to-Date Return16.56%

5-Day Price Return-5.94%

EPS Normalized (Annual)$-0.05

ROA (5Y Avg)-1.76%

Net Profit Margin (Annual)-18.83%

Month-to-Date Return-6.40%

Cash Flow / Share (TTM)$-3.86

EBITD / Share (Annual)$-0.35

Operating Margin (Annual)-145.27%

LT Debt / Equity (Annual)21.15x

P/CF (TTM)7.05x

ROI (5Y Avg)37.50%

P/E Excl Extra (TTM)135.01x

LT Debt / Equity (Quarterly)21.15x

EPS Basic Excl Extra (TTM)$-0.02

P/TBV (Quarterly)1.09x

P/B Ratio (Annual)0.70x

Inventory Turnover (TTM)-1.60x

Pretax Margin (TTM)-8.04%

Book Value / Share (Annual)$2.32

Price vs S&P 500 (13W)-10.45%

Beta0.66x

P/FCF (Annual)9.07x

Revenue / Share (TTM)$0.28

ROE (TTM)-0.80%

52-Week Low$1.03

vGradeB

gGradeD

mGradeB

vgmGradeC

TXMD Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2023	Aug 14, 2023	-$0.07	-$0.24	-242.86%(-$0.17)
Q1 2023	May 15, 2023	$0.06	-$0.24	-500.00%(-$0.30)
Q4 2022	Apr 8, 2023	-$1.11	$8.23	+841.44%(+$9.34)
Q3 2022	Nov 14, 2022	-$2.04	-$3.13	-53.43%(-$1.09)

TXMD Analyst Recommendations

Nov 2023

Dec 2023

Jan 2024

Feb 2024

2.17

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
TXMDTherapeuticsMD, Inc.	B	D	B	6.7x	27.8%	100.0%	—	$1.90
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About TherapeuticsMD, Inc.

TherapeuticsMD is a pharmaceutical royalty company that generates revenue from women's health products licensed to Mayne Pharma for U.S. commercialization, including IMVEXXY, BIJUVA, ANNOVERA, and prescription prenatal vitamins. By licensing its portfolio to an established pharmaceutical partner, the company collects royalties while minimizing operational expenses.